Orthopediatrics Corp. KIDS
Medical/Dental Instruments · IPO 2017 · data as of November 13, 2026
Orthopediatrics Corp. (KIDS) is a healthcare company listed in the US with a market value of about $845M. In the twelve months to September 30, 2026 it had revenue of $264M and net income of -$34M, a net margin of -12.8%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 265.6, 5-year revenue growth of 27% a year, a 5-year average ROIC of -7%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 84% below the current price.
About Orthopediatrics
Orthopediatrics is listed in the US and classified in medical/dental instruments, IPO year 2017. Revenue went from $31M in 2015 to $236M in 2025, growth of about 22.5% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 12% over three years (dilution for shareholders). It spends 4% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $264M | $236M | $205M | $149M | $122M | $98M | $71M | $73M | $58M | $46M | $37M |
| Net income | -$34M | -$40M | -$38M | -$21M | $1M | -$16M | -$33M | -$14M | -$12M | -$9M | -$7M |
| Free cash flow | $3M | -$16M | -$41M | -$44M | -$32M | -$21M | -$29M | -$30M | -$21M | -$12M | -$5M |
| EPS (diluted) | $-1.43 | $-1.69 | $-1.64 | $-0.92 | $0.06 | $-0.84 | $-1.82 | $-0.94 | $-0.96 | $-5.86 | $-7.14 |
| Net margin | -12.8% | -16.8% | -18.5% | -14.1% | 1.0% | -16.6% | -46.4% | -18.9% | -20.9% | -19.6% | -17.6% |
| ROIC | — | -6.7% | -7.2% | -6.8% | -5.3% | -7.4% | -11.1% | -5.4% | -9.3% | -8.9% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $30.75, 5% below the current price; targets range from $27.00 to $38.00; the consensus rating is “none”; expected EPS is $-1.09 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Orthopediatrics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 84% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Orthopediatrics pay a dividend?
Not currently.
Is Orthopediatrics a good stock to buy?
We do not give buy or sell advice. Orthopediatrics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.